I

I-MAB

D
IMAB
USD
-0.01
(-0.9174%)
Market Closed
12,083.00
Volume
-0.09
EPS
-
Div Yield
-0.478851
P/E
83,782,872.72
Market Cap
Today
-0.9174%
1 Week
1.408%
1 Month
-26.531%
6 Months
-40.659%
12 Months
-33.333%
Year To Date
-43.158%
All Time
0%

Title:
I/MAB

Sector:
Healthcare
Industry:
Biotechnology
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Do you need help or have a question?